Castle Biosciences, Inc.
Castle Biosciences, Inc. (CSTL) Revenue
Annual & quarterly revenue history · segment & region breakdown
CSTL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCastle Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.34B, an increase of 3.66% year-over-year from $0.34B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.34B | +$0.01B | +3.66% |
| 2024-12-31 | $0.33B | +$0.11B | +51.09% |
| 2023-12-31 | $0.22B | +$0.08B | +60.38% |
| 2022-12-31 | $0.14B | +$0.04B | +45.65% |
| 2021-12-31 | $0.09B | +$0.03B | +50.18% |
| 2020-12-31 | $0.06B | +$0.01B | +20.79% |
| 2019-12-31 | $0.05B | +$0.03B | +127.62% |
| 2018-12-31 | $0.02B | +$0.01B | +65.67% |
| 2017-12-31 | $0.01B | — | — |
Compare revenue vs peers
Medical - Diagnostics & ResearchCompare CSTL revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Castle Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Castle Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Castle Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CSTL revenue · 4 questionsCSTL's trailing twelve-month (TTM) revenue is $0.34B. That is an increase of 3.66% year-over-year from $0.34B in FY2025.
▸ Source: FMP · Castle Biosciences, Inc. SEC filings · GAAP · Castle Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026